Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis

7Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Venous thromboembolism (VTE) is one of the leading causes of post-operative morbidity and mortality. Over previous decades, heparin and warfarin were the predominant therapeutic options for post-operative thromboprophylaxis. However, their use is limited by drawbacks including a narrow therapeutic range, numerous food and drug interactions, and the need for regular monitoring for dose adjustments. Recently, direct oral anticoagulants (DOACs), such as dabigatran etexilate (a direct thrombin inhibitor) and apixaban, rivaroxaban and edoxaban (direct factor Xa inhibitors), have been developed to overcome these issues. DOACs have shown promising results in Phase III clinical trials for post-operative VTE prophylaxis. This review summarises the pharmacological profile of DOACs and highlights the use of DOACs in post-operative VTE prophylaxis based on the available clinical trial data.

Cite

CITATION STYLE

APA

Tun, H. N., Kyaw, M. T., Rafflenbeul, E., & Suastegui, X. L. (2022). Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis. European Cardiology Review , 17. https://doi.org/10.15420/ecr.2021.55

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free